Product Description
BMS-986397 is being developed by Bristol-Myer Squibb for the treatment of Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04951778?term=BMS-986397&draw=2&rank=1)
Mechanisms of Action: CK1a Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, Spain, United Kingdom, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CC-91633-AML-001 | P1 |
Recruiting |
Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia |
2026-05-05 |